AR070534A1 - Agonistas de receptores muscarinicos - Google Patents

Agonistas de receptores muscarinicos

Info

Publication number
AR070534A1
AR070534A1 ARP090100687A ARP090100687A AR070534A1 AR 070534 A1 AR070534 A1 AR 070534A1 AR P090100687 A ARP090100687 A AR P090100687A AR P090100687 A ARP090100687 A AR P090100687A AR 070534 A1 AR070534 A1 AR 070534A1
Authority
AR
Argentina
Prior art keywords
alkyl
heterocycloalkyl
heteroaryl
cycloalkyl
independently
Prior art date
Application number
ARP090100687A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR070534A1 publication Critical patent/AR070534A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composiciones farmacéuticas que incluyen los compuestos proceso e intermediario. Son utiles en terapia, en particular en el tratamiento del dolor, alzheimer y esquizofrenia. Reivindicacion 1: Un compuesto de Formula 1: o una sal farmacéuticamente aceptable del mismo; en la que: Y es -CR3R4-, -NR5-, -O-, o -S-; X es -CR6R7-, -NR8-, -O-, o -S-; con la condicion de que Y sea -CR3R4- o X sea -CR6R7-; cada A es, independientemente, alquilo de C1-3, o dos A están enlazados juntos para formar un puente de alquileno de C1-3; R1 es hidrogeno, alquilo de C1-6, o haloalquilo de C1-6; R2 es -C(O)ORa, -C(O)Rb, -C(O)NRcRd, alquilo de C1-6, haloalquilo de C1-6, cicloalquilo de C3-7, cicloalquil C3-7-alquilo de C1-3, heterocicloalquilo de C3-7, heterocicloalquil C3-7-alquilo de C1-3, aril C6-10-alquilo de C1-3, heteroarilo de C3-9, o heteroaril C3-9alquilo de C1-3 en el que los anillos de dichos arilo C6-10 aril de C6-10-alquilo de C1-3, heteroarilo de C3-9, y heteroaril C3-9-alquilo de C1-3 están cada uno opcionalmente sustituidos con 1, 2, 3 o 4 grupos seleccionados independientemente; en el que los anillos de dichos cicloalquilo de C3-7, cicloalquil C3-7-alquilo de C1-3, heterocicloalquilo de C3-7, y heterocicloalquil C3-7-alquilo de C1-3 están cada uno opcionalmente sustituidos con 1, 2, 3 o 4 grupos R10 seleccionados independientemente; y en el que dichos alquilo de C1-6, alquenilo de C2-6, alquinilo de C2-6, haloalquilo de C1-6, alcoxi de C1-6, y haloalcoxi de C1-6 están cada uno opcionalmente sustituidos con 1, 2 o 3 grupos R11 seleccionados independientemente: R3, R4, R6, y R7 son cada uno, independientemente, hidrogeno, fluoro, alquilo de C1-4, alcoxi de C1-4-metilo, ciano-alquilo de C1-4 o haloalquilo de C1-4; R5 y R8 son cada uno, independientemente, hidrogeno, alquilo de C1-4, o haloalquilo de C1-4: cada R9 y R10 es, independientemente, fenilo, cicloalquilo de C3-6, heterocicloalquilo de C2-5 , heteroarilo de C3-5, -CN, -SRe, -ORe, O(CH2)r-ORe, Re, -C(O)-Re, -CO2Re, -SO2Re, -SO2NReRf, halogeno, -NO2, NReRf, -(CH2)rNReRf, o -C(O)NReRf: cada R11 es, independientemente, -CN, -NO2, ORe, o NReRf; Ra, Rb, Rc, y Rd son cada uno, independientemente, hidrogeno, alquilo de C1-7, alquenilo de C2-6, alquinilo de C2-6, haloalquilo de C1-6, cicloalquilo de C3-7, cicloalquil C3-7 alquilo de C1-3, heterocicloalquilo de C3-7, heterocicloalquil C3-7-alquilo de C1-3, arilo de C6-10, aril C6-10-alquilo de C1-3, heteroarilo de C3-9, o heteroaril C3-9-alquilo de C1-3: en los que los anillos de dichos arilo de C6-10, aril C6-10-alquilo de C1-3, heteroarilo de C3-9, y heteroaril C3-9-alquilo de C1-3 están cada uno opcionalmente sustituidos con 1, 2, 3 o 4 grupos R12 seleccionados independientemente; en los que los anillos de dichos cicloalquilo de C3-7, cicloalquil C3-7-alquilo de C1-3, heterocicloalquilo de C3-7, y heterocicloalquil C3-7-alquilo de C1-3, están cada uno opcionalmente sustituidos con 1, 2, 3 o 4 grupos R13 seleccionados independientemente: y en los que dicho alquilo de C1-7, alquenilo de C2-6, alquinilo de C2-6, haloalquilo de C1-6, alcoxi de C1-7, y haloalcoxi de C1-6 están cada uno opcionalmente sustituidos con 1, 2 o 3 grupos R14 seleccionados independientemente: cada R12, R13, y R14 es, independientemente, fenilo, cicloalquilo de C3-6, heterocicloalquilo de C2-5, heteroarilo de C3-5, -CN, -SRg, -ORg, -O(CH2)r-ORg, Rg, -C(O)-Rg, -CO2Rg, -SO2Rg, -SO2NRgRh, halogeno, -NO2, -NRgRh, -(CH2)NRgRh, o -C(O)-NRgRh: cada Re, Rf, Rg y Rh es, independientemente, hidrogeno, alquilo de C1-6, alquenilo de C2-6 o haloalquilo de C1-6, m es 1, 2 o 3: p es 0, 1 o 2: q es un numero entero de 0 a [6+(px2)]; y r es 1, 2, 3 o 4; con la condicion de que el compuesto no sea 4'-metil-4-((4aS,8aS)-2-oxooctahidroquinoxalin-1(2H)-il)-1,4'-bipiperidin-1'-carboxilato de isopropilo, 4-[4-[(4aS,8aS)2-oxo-3,4,4a,5,6,7,8,8a-octahidroquinoxalin-1-il]-1-piperidil]-4-metil-piperidin-1-carboxilato de isopropilo, (3S)-3-[4-[(4aS,8aS)-3-oxo-4a,5,6,7,8,8a-hexahidrobenzo[b][1,4]oxazin-4-iI]-1-piperidil]pirrolidin-1-carboxilato de isopropilo, 4-[4-[(4aR,8aR)-2-oxo-4a,5,6,7,8,8a-hexahidro-4H-benzo[d][1,3]oxazin-1-il]-1-piperidil]piperidin-1-carboxilato de terc-butilo, 4-[4-[(4aS,8aS)-3-oxo-4a,5,6,7,8,8a-hexahidrobenzo[b][1,4]oxazin-4-il]-1-piperidil]-4-metil-piperidin-1-carboxilato de isopropilo, (4aS,8aS)-1-[1-[1-(2-metilbenzoil)-4-piperidil]-4-piperidil]-4a,5,6,7,8,8a-hexahidro-4H-benzo[d][1,3]oxazin-2-ona, 4-[4-[(4aS,8aS)-3-oxo-4a,5,6,7,8,8a-hexahidrobenzo[b][1,4]oxazin-4-il]-1-piperidil]piperidin-1-carboxilato de terc-butilo, 4-[4-[(4aS,8aS)-2-oxo-4a,5,6,7,8,8a-hexahidro-4H-benzo[d][1,3]oxazin-1-il]-1-piperidil]piperidin-1-carboxilato de metilo, o una sal farmacéuticamente aceptable de los mismos.
ARP090100687A 2008-02-28 2009-02-27 Agonistas de receptores muscarinicos AR070534A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3213808P 2008-02-28 2008-02-28

Publications (1)

Publication Number Publication Date
AR070534A1 true AR070534A1 (es) 2010-04-14

Family

ID=41013656

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100687A AR070534A1 (es) 2008-02-28 2009-02-27 Agonistas de receptores muscarinicos

Country Status (16)

Country Link
US (1) US20090221567A1 (es)
EP (1) EP2257543A4 (es)
JP (1) JP2011513302A (es)
KR (1) KR20100131463A (es)
CN (1) CN102015687A (es)
AR (1) AR070534A1 (es)
AU (1) AU2009217823A1 (es)
BR (1) BRPI0907992A2 (es)
CA (1) CA2716855A1 (es)
CL (1) CL2009000445A1 (es)
MX (1) MX2010009395A (es)
PE (1) PE20091433A1 (es)
RU (1) RU2010135253A (es)
TW (1) TW200940522A (es)
UY (1) UY31672A1 (es)
WO (1) WO2009108117A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200815405A (en) * 2006-06-09 2008-04-01 Astrazeneca Ab Novel compounds
TW200813018A (en) * 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
US9187451B2 (en) 2011-11-18 2015-11-17 Heptares Therapeutics Limited Muscarinic M1 receptor agonists
WO2014045031A1 (en) * 2012-09-18 2014-03-27 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic m1 receptor agonists
US9593106B2 (en) 2013-02-07 2017-03-14 Heptares Therapeutics Limited Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513742D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
WO2024088408A1 (zh) * 2022-10-28 2024-05-02 纽欧申医药(上海)有限公司 一种含氮杂环化合物、其药学上可接受的盐及其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2307999A (en) * 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
WO2003105781A2 (en) * 2002-06-17 2003-12-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US8288412B2 (en) * 2005-09-30 2012-10-16 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
TW200815405A (en) * 2006-06-09 2008-04-01 Astrazeneca Ab Novel compounds
TW200813018A (en) * 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
TW200940522A (en) 2009-10-01
JP2011513302A (ja) 2011-04-28
BRPI0907992A2 (pt) 2017-06-13
US20090221567A1 (en) 2009-09-03
KR20100131463A (ko) 2010-12-15
RU2010135253A (ru) 2012-04-10
PE20091433A1 (es) 2009-10-24
EP2257543A4 (en) 2012-03-21
CA2716855A1 (en) 2009-09-03
EP2257543A1 (en) 2010-12-08
CL2009000445A1 (es) 2011-05-06
CN102015687A (zh) 2011-04-13
AU2009217823A1 (en) 2009-09-03
WO2009108117A1 (en) 2009-09-03
MX2010009395A (es) 2010-09-24
UY31672A1 (es) 2009-09-30

Similar Documents

Publication Publication Date Title
AR070534A1 (es) Agonistas de receptores muscarinicos
AR058010A1 (es) Derivados biciclicos como inhibidores de p38 y composicion farmaceutica en base al compuesto
AR068057A1 (es) Esteres de 1-fenil-2-(3,5-dicloro)-piridina, metodo de preparacion de los mismos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de enfermedades del tracto respiratorio.
AR080187A1 (es) Derivados pirazolicos condensados con heterociclos nitrogenados utiles en el tratamiento de enfermedades inflamatorias, inmunitarias y/o trastornos mieloploliferativos y composiciones farmaceuticas que los contienen.
AR070744A1 (es) Agonistas de los receptores muscarinicos, composiciones, metodos de tratamiento en que se emplean y sus procesos de preparacion -176
ES2521596T3 (es) Combinación del compuesto GlyT1 con antipsicóticos
AR071717A1 (es) Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
AR063015A1 (es) Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer
PE20160751A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6
PE20141075A1 (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
PE20090493A1 (es) DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
AR075531A1 (es) Derivados de piperazin-ciclopropil benzamidas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central, tales como alzheimer y esquizofrenia, entre otros
AR081369A1 (es) Compuestos de 2-5-6-7-tetrahidro-(1,4) oxazepin-3-ilamina o 2,3,6,7-tetrahidro-(1,4) oxazepin-5-ilamina, sus procesos de obtencion y composiciones farmaceuticas que los contienen
AR079689A1 (es) Derivados de imidazo[1,2a]piridina, composiciones farmaceuticas que los comprenden y uso de los mismos en trastornos mieloproliferativos, leucemia y enfermedades inmunologicas e inflamatorias.
PE20091095A1 (es) Moduladores de gamma secretasa
CO6251260A2 (es) Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c.
PE20150399A1 (es) Nuevos derivados de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR078163A1 (es) Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes
AR084515A1 (es) Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras
RU2011107437A (ru) Ингибиторы кинуренин-3-моноксигеназы
PE20090622A1 (es) Nuevos derivados de bencimidazol sustituido
DOP2006000125A (es) Derivados de ciclohexanosulfonilo como inhibidores de glyt1 para tratar esquizofrenia
PE20150218A1 (es) Nuevos derivados fosfatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR077147A1 (es) Compuestos biciclicos y triciclicos como inhibidores de kat ii

Legal Events

Date Code Title Description
FB Suspension of granting procedure